R F Labianca

Summary

Country: Italy

Publications

  1. doi Colon cancer
    Roberto Labianca
    Ospedali Riuniti, Bergamo, Italy
    Crit Rev Oncol Hematol 74:106-33. 2010
  2. doi Axillary recurrence in sentinel lymph node-negative breast cancer patients
    P Poletti
    Department of Medical Oncology, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Ann Oncol 19:1842-6. 2008
  3. doi Adverse effects associated with non-opioid and opioid treatment in patients with chronic pain
    Roberto Labianca
    Oncology Unit, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Clin Drug Investig 32:53-63. 2012
  4. doi Adverse effects associated with non-opioid and opioid treatment in patients with chronic pain
    Roberto Labianca
    Oncology Unit, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Clin Drug Investig 32:53-63. 2012
  5. pmc Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study
    Sandro Barni
    Oncology Department, San Filippo Neri Hospital, Via Martinotti 20, Rome, 00135, Italy
    J Transl Med 9:179. 2011
  6. pmc Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis
    Mario Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Ancona, Italy
    BMC Cancer 9:303. 2009
  7. doi Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial
    R Labianca
    Oncologia Medica, Ospedali Riuniti, Bergamo
    Ann Oncol 22:1236-42. 2011
  8. ncbi Screening and diagnosis for colorectal cancer: present and future
    Roberto Labianca
    Unit of Medical Oncology Ospedali Riuniti di Bergamo, Italy
    Tumori 96:889-901. 2010
  9. ncbi New strategies in colon cancer adjuvant therapy
    R Labianca
    Oncology Unit Ospedali Riuniti, Bergamo, Italy
    Ann Oncol 17:vii51-4. 2006
  10. ncbi Disease management considerations: disease management considerations
    R F Labianca
    Medical Oncology Unit, Ospedali Riuniti, Bergamo, Italy
    Drugs 61:1751-64. 2001

Collaborators

Detail Information

Publications22

  1. doi Colon cancer
    Roberto Labianca
    Ospedali Riuniti, Bergamo, Italy
    Crit Rev Oncol Hematol 74:106-33. 2010
    ..This report summarizes the most important achievements in this field and provides the readers useful suggestions for their professional practice...
  2. doi Axillary recurrence in sentinel lymph node-negative breast cancer patients
    P Poletti
    Department of Medical Oncology, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Ann Oncol 19:1842-6. 2008
    ..SLNB is predictive of axillary node status. Major concern is the occurrence of a false-negative SLN. Purpose of this study is to determine the rate of axillary recurrence in our series of unselected patients...
  3. doi Adverse effects associated with non-opioid and opioid treatment in patients with chronic pain
    Roberto Labianca
    Oncology Unit, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Clin Drug Investig 32:53-63. 2012
    ..Balanced against the adverse effects of pain management medications, there is a need to be mindful of the widespread, often serious, adverse consequences of poorly managed pain itself...
  4. doi Adverse effects associated with non-opioid and opioid treatment in patients with chronic pain
    Roberto Labianca
    Oncology Unit, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Clin Drug Investig 32:53-63. 2012
    ..Balanced against the adverse effects of pain management medications, there is a need to be mindful of the widespread, often serious, adverse consequences of poorly managed pain itself...
  5. pmc Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study
    Sandro Barni
    Oncology Department, San Filippo Neri Hospital, Via Martinotti 20, Rome, 00135, Italy
    J Transl Med 9:179. 2011
    ..The aims of this retrospective analysis were to evaluate the thromboembolic risk and the benefit of thromboprophylaxis according to type of chemotherapy...
  6. pmc Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis
    Mario Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Ancona, Italy
    BMC Cancer 9:303. 2009
    ..Based on these findings we investigated the correlation between both FISH and CISH EGFR GCN and clinical outcome in K-RAS wild-type colorectal cancer treated with irinotecan-cetuximab...
  7. doi Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial
    R Labianca
    Oncologia Medica, Ospedali Riuniti, Bergamo
    Ann Oncol 22:1236-42. 2011
    ..The main end point was overall survival (OS), the secondary progression-free survival (PFS) and toxicity...
  8. ncbi Screening and diagnosis for colorectal cancer: present and future
    Roberto Labianca
    Unit of Medical Oncology Ospedali Riuniti di Bergamo, Italy
    Tumori 96:889-901. 2010
    ..However, only 10% of patients whose cancer has spread to distant parts of the body survive 5 years. Diagnosis at an early stage aims to reduce the incidence of tumors in an advanced stage and hence mortality...
  9. ncbi New strategies in colon cancer adjuvant therapy
    R Labianca
    Oncology Unit Ospedali Riuniti, Bergamo, Italy
    Ann Oncol 17:vii51-4. 2006
    ..Other open questions include duration of therapy and whether there is a real possibility of selecting patients for treatment on the basis of prognostic factors...
  10. ncbi Disease management considerations: disease management considerations
    R F Labianca
    Medical Oncology Unit, Ospedali Riuniti, Bergamo, Italy
    Drugs 61:1751-64. 2001
    ..To achieve further progress in knowledge in this field, we strongly recommended that more and more patients are included in clinical trials...
  11. ncbi Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients
    M Mandala
    Unit of Medical Oncology, Ospedali Riuniti, Bergamo, Italy
    Ann Oncol 18:1660-5. 2007
    ..The aim was to investigate the outcomes associated with venous thromboembolism (VTE) among irresectable pancreatic cancer patients...
  12. ncbi The role of adjuvant chemotherapy in colon cancer
    R Labianca
    Medical Oncology Unit, Ospedali Riuniti, Bergamo, Italy
    Surg Oncol 16:S93-6. 2007
    ..Novel molecular and biological-oriented agents are being studied, with promising date...
  13. ncbi The development of clinical research in CRC
    R Labianca
    Department of Medical Oncology, Ospedali Riuniti, Bergamo, Italy
    Ann Oncol 16:iv37-43. 2005
  14. pmc A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer
    F Graziano
    Medical Oncology Unit, Hospital of Urbino, Italy
    Br J Cancer 89:1428-32. 2003
    ..The weekly PLF regimen resulted safe and effective in elderly patients with advanced GC. This outpatient regimen is based on old and low-cost drugs and it may represent an alternative to new and more expensive combinations...
  15. doi Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database
    M Mandala
    Unit of Medical Oncology, Ospedali Riuniti Bergamo, Largo Barozzi 1, Bergamo 24126, Italy
    Eur J Cancer 45:2537-45. 2009
    ....
  16. doi Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial
    M Mandala
    Department of Oncology and Hematology, Ospedali Riuniti di Bergamo, Largo Barozzi 1, Bergamo, Italy
    Ann Oncol 21:871-6. 2010
    ..Acquired and inherited risk factors for venous thromboembolism (VTE) and the incidence of symptomatic VTE were investigated in patients on adjuvant chemotherapy for breast or gastrointestinal cancer (GI)...
  17. ncbi Challenges in the treatment of gastrointestinal tumours
    R Labianca
    Department of Oncology, Ospedali Riuniti, Bergamo, Italy
    Ann Oncol 17:v137-41. 2006
    ..In this review we have considered the three most important subgroups of gastrointestinal tumours (colorectal, gastric and pancreatic cancer), focusing on the state-of-the-art treatments...
  18. ncbi Population-based sentinel lymph node biopsy in early invasive breast cancer
    P Fenaroli
    Breast Cancer Unit, Surgical Department, Ospedali Riuniti, Bergamo, Italy
    Eur J Surg Oncol 30:618-23. 2004
    ..In the present study we analyse the impact of this procedure when systematically applied to all unselected women of a community-based Breast Cancer Unit (BCU)...
  19. ncbi New drugs and combinations in the palliative treatment of colon and rectal cancer
    G D Beretta
    Medical Oncology Unit, Ospedali Riuniti Bergamo, Italy
    Eur J Surg Oncol 27:595-600. 2001
    ..For nearly four decades, fluorouracil (5FU) has been the mainstay of treatment. New compounds active against colorectal cancer are now available. Several studies on this topic are ongoing...
  20. ncbi Perioperative or postoperative therapy for resectable gastric cancer?
    R Labianca
    Oncology Department Ospedali Riuniti, Bergamo, Italy
    Ann Oncol 19:v99-102. 2008
  21. pmc Gemcitabine plus vinorelbine in elderly or unfit patients with non-small cell lung cancer
    G D Beretta
    Medical Oncology Unit, Pneumology Unit, Radiotherapy Unit, Ospedali Riuniti, Largo Barozzi 1, Bergamo, 24100, Italy
    Br J Cancer 83:573-6. 2000
    ..6%. In conclusion, the results of this phase II study show that the combination of gemcitabine and vinorelbine is active and well tolerated in NSCLC, and thus encourage its use in elderly or unfit patients...
  22. ncbi Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM)
    M Mandala
    Division of Medical Oncology, Azienda Ospedaliera Treviglio Caravaggio, Treviglio Caravaggio Hospital P le Ospedale 1, 24047 Treviglio, Bergamo, Italy
    Crit Rev Oncol Hematol 59:194-204. 2006
    ....